Page 240 - ebook HCC

GENEVA, SWITZERLANDA, SWITZERLAND
PROGRAMME
EASL
238 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEV EASL HCC SUMMITHCC SUMMIT 239
239
238
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C28
LIVER STIFFNESS (LS) ASSESSED WITH Tab.1 Total population (n=58) 95% LCL-UCL
ACOUSTIC RADIATION FORCE IMPULSE Male (n%) 48 (83%)
65.7-70.8
68.3±9.8
(ARFI) CAN IDENTIFY PATIENTS AFFECTED BY Age (mean±ds) 16,188 ± 10,673 13,382.1-18,995.2
SFA (mm ) (mean±ds)
2
CHRONIC LIVER DISEASE (CLD) AT HIGHER RISK VFA (mm ) (mean±ds) 12,618.8 + 6,829.5 10,823.1-14,415.5
2
OF HEPATOCELLULAR CARCINOMA (HCC) Cirrhosis (n) % 54 (93%) 5.6-6.2
5.9±1
CP score (mean±ds)
Meld score (mean±ds) 7.6±3.3 6.7-8.6
BCLC(n)(%)
Adriano De Santis , Chiara Bassanelli , Marinella Lupo , Claudia Iegri , B /C 25 (42%)33 (58%)
1
1
1
1
Carmela A. Di Ciesco , Giulia Gallusi , Mariana Forlino , Adolfo F. Attili 1 ECOG (n)(%)
1
1
1
1 Clinical Medicine, La Sapienza University, Rome, Italy 0/1 43 (74%)15 (26%)
Tab.2 SFA VFA
Corresponding author’s e-mail: chiara.bassanelli@gmail.com
> median ≤ median (29pts) p > ≤ p
(29 pts) median(29pts) median(29pts)
CP score (mean±ds) 5.8±1.04 6.2±1.01 ns 6±1.07 6±1.04 ns
Introduction: ARFI is a noninvasive method to measure LS during the routine ultrasound Meld score 7.7±3.5 7.6±3.4 ns 7.9±3.4 7.4±3.4 ns
examination. It has already been demonstrated that LS measured by Fibroscan can be a (mean±ds)
prognostic factor for major complications of CLD. BCLC C (n%) 15 (52%) 18 (62%) ns 15 (52%) 18 (62%) ns
ECOG 0 (n%) 24(82%) 19 (66%) ns 22 (76%) 21 (72%) ns
Aims: The aim of our study is correlate LS assessed with ARFI and occurrence of HCC.
Conclusions: Our preliminary data suggest that LS measured with ARFI could define the
Methodology: Two hundred-nine patients affected by chronic liver disease with different risk of occurrence of HCC in patients affected by CLD as already shown for Fibroscan.
etiology were included in our study:62.5% had a clinical diagnosis of cirrhosis(Child Pugh’s Further data are required.
score 6.4±1.5/MELD 8.1±4.7).In all patients LS was evaluated at the enrollment: the
assessment was made on the right lobe and the medium value of ten measurements was
considered as result. We transform the obtained result expressed in m/s in kPa applying
Young’s module. We exclude from analysis patients with diagnosis of hepatocellular
CLINICAL POSTER ABSTRACTS of LS obtained in our population:≤15.6 kPa(GROUP1-G1; n95) and >15.6(GROUP2-G2; CLINICAL POSTER ABSTRACTS
carcinoma (n22) and those with incident HCC occurred in the first six months after the
enrollment (n2). We stratify the remaining in two groups choosing as cut off the median value
n87). The median follow up(FU) is 561 days (range:12-1120).
Results: HCC develop in 10 pts; 5 in G1 and 5 in G2. As Kaplan Meyer’s curves show
(Fig 1), the cumulative incidence (CI) of HCC increase accordingly to LS values (Log Rank
p=0.001). The incidence of HCC after 24 months of FU is 6.8% in G2 vs 3 % in G1.The
mean time of occurrence of HCC in G2 was 397±331 days vs 556±304 in G1(p=ns).